Halloran C - Search Results

1

Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.

Barrera LN, Evans A, Lane B, Brumskill S, Oldfield FE, Campbell F, Andrews T, Lu Z, Perez-Mancera PA, Liloglou T, Ashworth M, Jalali M, Dawson R, Nunes Q, Phillips PA, Timms JF, Halloran C, Greenhalf W, Neoptolemos JP, Costello E. Barrera LN, et al. Among authors: halloran c. Cancer Res. 2020 Jul 1;80(13):2861-2873. doi: 10.1158/0008-5472.CAN-19-3534. Epub 2020 May 11. Cancer Res. 2020. PMID: 32393661

2

Gene therapy for pancreatic cancer--current and prospective strategies.

Halloran CM, Ghaneh P, Neoptolemos JP, Costello E. Halloran CM, et al. Surg Oncol. 2000 Dec;9(4):181-91. doi: 10.1016/s0960-7404(01)00011-1. Surg Oncol. 2000. PMID: 11476989 Review.

3

Complications of pancreatic cancer resection.

Halloran CM, Ghaneh P, Bosonnet L, Hartley MN, Sutton R, Neoptolemos JP. Halloran CM, et al. Dig Surg. 2002;19(2):138-46. doi: 10.1159/000052029. Dig Surg. 2002. PMID: 11979003 Free article. Review.

4

5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.

Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos JP, Costello E. Halloran CM, et al. J Gene Med. 2004 May;6(5):514-25. doi: 10.1002/jgm.540. J Gene Med. 2004. PMID: 15133762

5

Current standards of surgery for pancreatic cancer.

Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Alexakis N, et al. Among authors: halloran c. Br J Surg. 2004 Nov;91(11):1410-27. doi: 10.1002/bjs.4794. Br J Surg. 2004. PMID: 15499648 Review.

6

Trials of gene therapy for pancreatic carcinoma.

Halloran CM, Ghaneh P, Costello E, Neoptolemos JP. Halloran CM, et al. Curr Gastroenterol Rep. 2005 Jun;7(3):165-9. doi: 10.1007/s11894-005-0028-7. Curr Gastroenterol Rep. 2005. PMID: 15913472 Review. No abstract available.

7

Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy.

Halloran CM, Ghaneh P, Connor S, Sutton R, Neoptolemos JP, Raraty MG. Halloran CM, et al. Br J Surg. 2008 Apr;95(4):453-9. doi: 10.1002/bjs.6043. Br J Surg. 2008. PMID: 18161888

8

Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach.

Raraty MG, Halloran CM, Dodd S, Ghaneh P, Connor S, Evans J, Sutton R, Neoptolemos JP. Raraty MG, et al. Ann Surg. 2010 May;251(5):787-93. doi: 10.1097/SLA.0b013e3181d96c53. Ann Surg. 2010. PMID: 20395850

9

Surgical oncology: PBD-better stents in specialized centers are needed.

Neoptolemos JP, Halloran CM. Neoptolemos JP, et al. Nat Rev Clin Oncol. 2010 May;7(5):244-6. doi: 10.1038/nrclinonc.2010.45. Nat Rev Clin Oncol. 2010. PMID: 20428218 No abstract available.

10

Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study.

Halloran CM, Cox TF, Chauhan S, Raraty MG, Sutton R, Neoptolemos JP, Ghaneh P. Halloran CM, et al. Pancreatology. 2011;11(6):535-45. doi: 10.1159/000333308. Epub 2011 Nov 15. Pancreatology. 2011. PMID: 22094930

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

121 results

Search Page